A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression

Yukako Hamano, Toshikazu Moriwaki, Keii To, Takahisa Watahiki, Takeshi Yamada, Shingo Sakashita, Ichinosuke Hyodo
2019 Internal medicine (Tokyo. 1992)  
The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with
more » ... G 2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size.
doi:10.2169/internalmedicine.1809-18 fatcat:vlv4thp225epzpznflgbkw6trq